3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
14
Breast Neoplasms
12
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Skin Diseases
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Metastatic Neuroendocrine Prostate Cancer
1
Inflammatory Breast Neoplasms
1
Dementia
1
Cognitive Dysfunction
1
Carcinoma, Ductal, Breast
1
Interventions
pembrolizumab
24
Carboplatin
21
Paclitaxel
20
olaparib
19
Magnetic Resonance Spectroscopy
14
Bevacizumab
14
Cyclophosphamide
12
Specimen Handling
11
Nivolumab
11
Gemcitabine
11
Taxes
10
niraparib
8
Cisplatin
8
Biopsy
8
liposomal doxorubicin
7
fludarabine
7
Surveys and Questionnaires
6
Immunoglobulin G
6
Doxorubicin
6
Disulfides
6
durvalumab
5
palbociclib
4
oregovomab
4
X-Rays
4
Ipilimumab
4
Fulvestrant
4
mirvetuximab soravtansine
3
ipatasertib
3
defactinib
3
cediranib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ovarian Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04931342
2026-06-08
BOUQUET
Hoffmann-La Roche
Phase 2
Active not recruiting
176 enrolled